CIBBIM - Nanomedicine
CIBBIM – Nanomedicine Drug Delivery and Targeting
Simó Schwartz
Researchers
Ibane Abasolo Olaortúa, Carmen Domínguez Luengo, Eva Baldrich Rubio, Yolanda Fernández Amurgo, Petra Gener, Joaquin Seras Franzoso, Khuloud Sweimeh, Helena Pla Solans, Laia Foradada Felip , Víctor Rodríguez Sureda
Researchers in training
Diana Fernandes de So Rafael, Helena Xandri i Monje , Eider Bergareche Barbeito , Guillem Jorba Argemí
Nursing, Technical, and Administrative Staff
Laura Barberà Ferrando , Anna Pérez Martín , Mª Eugènia López Sánchez , Montse Capella Tomás, Aida Castellanos Paez, Laura García Latorre, Natalia García Aranda, Alicia García Robaina, Sandra Mancilla Zamora, Marc Macaya Font
SUMMARY
The group on Drug Delivery and Targeting seeks on the one hand, the identification of new disease biomarkers and therapeutic targets, with special focus on cancer molecular pathways and in the physiopathology of low prevalent diseases; and on the other hand, the development of new drug delivery strategies as applied nanomedicine, with a particular interest into new targeting approaches for clinical applications and further, new diagnostic tools based on nanotechnology applications for clinical uses.
Among our projects are a new EuroNanoMed II project focused in nanomedicine applications involving SME’s in which animal models are being used for preclinical validation of new therapies directed against tumor cells (DiamESTar), and four additional projects, two of them from Marató TV3 (Nanofabry: focused in drug delivery systems for the Fabry disease and Pentri: for active targeting against cancer stem cells), two industry oriented projects (INNPACTO and RETOS) together with SMEs and focused into scale-up and preclinical validation of drug delivery systems including the establishment of GMP pilot lines and additional National grants. Several in vitro and in vivo cancer models have been generated by the group for preclinical testing of nanomedicines, including the generation of specific bioluminescent cancer stem cell models. Further, several projects are focused into the molecular mechanisms of low-prevalent diseases. Particularly, the study of the cellular mechanisms involved in the pathogenesis of lysosomal storage diseases and in other low-prevalence pathologies such as congenital heart disease. We have reported that imbalance of angiogenic-antiangiogenic factors is associated with developmental defects of the human heart. Finally, a new research line (DINA) has been opened with a main goal: the exploitation of nanostructures, nanomaterials and nanocomponents as transducers, biofunctionalization platforms and signal amplifiers for fast assay and biosensor development. A total of 14 patents have been issued by our group. Three patents from the group were either issued or advanced to National Fases in 2014. One related to new biomarkers as predictors of adverse reaction for implanted biomaterials, the second regarding the use of unilamelar vesicles for enzyme replacement therapy in lysosomal storage diseases and the third regarding a new biosensing system for clinical purposes.
PUBLICATIONS
- Candiota AP, Acosta M, Simões RV, Delgado-Goñi T, Lope-Piedrafita S, Irure A, Marradi M, Bomati-Miguel O, Miguel-Sancho N, Abasolo I, Schwartz S Jr, Santamaria J, Penadés S, Arús C. A new ex vivo method to evaluate the performance of candidate MRI contrast agents: a proof-of-concept study.
J Nanobiotechnology. 2014 Apr 5;12:12. doi: 10.1186/1477-3155-12-12.
FI: 4,078 - E. Llurba, O. Sánchez, Q. Ferrer, KH. Nicolaides, A. Ruiz, C. Domínguez, J. Sánchez-de-Toledo, B. García-García, G. Soro, S. Arévalo, M. Goya, S. Pérez-Hoyos, J. Alijotas-Reig, E. Carreras, L. Cabero. Maternal and Foetal Angiogenic Imbalance in Congenital Heart Defects
European Heart Journal, 2014. 35(11): 701-707. PMID:24159191
FI: 14.097 - Francesca Mateo, Óscar Meca-Cortés, Toni Celià-Terrassa, Yolanda Fernández, Ibane Abasolo, Lourdes Sánchez-Cid, Raquel Bermudo, Amaia Sagasta, Leonardo Rodríguez-Carunchio, Mònica Pons, Verónica Cánovas, Mercedes Marín-Aguilera, Lourdes Mengual, Antonio Alcaraz, Simó Schwartz Jr, Begoña Mellado, Kristina Y Aguilera, Rolf Brekken, Pedro L Fernández, Rosanna Paciucci and Timothy M Thomson. SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations
Molecular Cancer 2014 Oct 21;13:237. doi: 10.1186/1476-4598-13-237
FI: 5,397 - Paulo Rodrigues, Irati Macaya, Sarah Bazzocco, Rocco Mazzolini, Elena Andretta, Higinio Dopeso, Silvia Mateo-Lozano, Josipa Bilic, Fernando Carton Garcıa, Rocio Nieto, Lucia Suarez-Lopez, Elsa Afonso, Stefania Landolfi, Javier Hernandez-Losa, Kazuto Kobayashi, Santiago Ramon y Cajal, Josep Tabernero, Niall C. Tebbutt, John M. Mariadason, Simo Schwartz Jr & Diego Arango RHOA inactivation enhances Wnt signalling and promotes colorectal cancer Received 5 May 2014 | Accepted 2 Oct 2014
Nature Communications | 5:5458 | DOI: 10.1038/ncomms6458
FI: 10,742 - Marques N, Sese M, Canovas V, Valente F, Bermudo R, de Torres I, Fernandez Y, Abasolo I, Fernandez PL, Contreras H, Castellon E, Celia-Terrassa T, Mendez R, Ramon Y Cajal S, Thomson TM, Paciucci R Regulation of protein translation and c-Jun expression by prostate tumor overexpressed
Oncogene 2014 Feb 27;33(9):1124-34. PMID: 23455324
FI: 8,559
MAIN RESEARCH PROJECTS
View- Targeting Combined Therapy to Cancer Stem Cells (NANOSTEM)
Ref: PI 11/1079
Funder Entity: Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III (FIS)
Duration: 2012-2014
PI: Simó Schwartz Navarro
Funding: 145.540,00 € - Development of nanomedicines for enzymatic replacement therapy in Fabry disease. Ref: MARTV3-2010-101230
Funder Entity: Fundación La Marató de TV3
Duration: 2011-2014
PI: Simó Schwartz Navarro
Funding: 214.925,00 € - Nanocomponents and Nanostructured Materials in Fast Assay and Biosensor Development for Diagnostic purposes
Ref: CP13/00052
Duration: from 2014 to 2016
Funder Entity: Fondo de Investigación Sanitaria
Funding: 121.500,00 €
PI: Eva Baldrich Rubio - Personalized nanomedicine for triple negative breast cancer stem cells
Ref: 337/C/2013
Duration: from 2014 to 2017
Funder Entity: Fundació La Marató de TV3
Funding Entity: 174.000,00 €
PI: Abasolo Olaortua, Ibane - Liberación dirigida de nanoconjugados de inhibidor de Alox5 contra células madre tumorales
Ref: PI14/02079
Duration: from 2015 to 2017
Funding Entity: Fondo de Investigación Sanitaria
PI: Simó Schwartz Navarro
Funding: 171.215,00 €
PATENTS
- PATENT: MARCADORES PARA LA SELECCIÓN DE TERAPIAS PERSONALIZADAS PARA EL TRATAMIENTO DEL CÁNCER (P200901817)
Date of registration: SEPTEMBRER, 2th 2009
EEUU: 13393215 (28/02/2012) - PATENT: NANOPARTÍCULAS DE SÍLICE PARA DIFUSIÓN INTRACELULAR DE AGENTES BIOACTIVOS POCO SOLUBLES (P201030502)
Date of registration: APRIL, 6th 2010
PCT/ES 2011/070232 (6/04/2011) - PATENT: DERIVADOS DE CAMPTOTECINA COMO AGENTES ANTITUMORALES (P201030775)
Date of registration: MAY, 21th 2010
PCT/ES/2011/070371 (23/05/2011) - PATENT: MÉTODO DE DETECCIÓN DE LA SUSCEPTIBILIDAD A DESARROLLAR EFECTOS SECUNDARIOS ADVERSOS RELACIONADOS CON BIOIMPLANTES (P1637ES01)
Date of registration: MARCH, 15th 2011
EEUU: 13695009 (1/04/2013) - PATENT: FUNCTIONALIZED LIPOSOMES USEFUL FOR THE DELIVERY OF BIOACTIVE COMPOUNDS
Number: 2194225
Date: JUNE, 29th 2012
PCT: PCT/EP2013/063646 (28/06/2013)